Pramel53, classified as a PRAME-like 53 gene and predicted to be active in the cytoplasm, represents a relatively understudied component of cellular physiology. The intricate details of its precise functions within the cell are yet to be fully elucidated. However, the predicted location in the cytoplasm suggests a role in orchestrating key cellular processes outside the nucleus. The PRAME-like family, to which Pramel53 belongs, shares homology with the cancer/testis antigen family and is known to be involved in diverse cellular functions, including cell cycle regulation, transcriptional control, and immune response modulation. Given the predictive activity in the cytoplasm, Pramel53 may play a crucial role in mediating signaling cascades and cellular responses to extracellular stimuli.
The inhibition of Pramel53, as outlined by various chemical compounds, unveils potential connections between this gene and critical cellular signaling pathways. The indirect inhibition through pathways like mTOR, p38 MAPK, PI3K/Akt, ubiquitin-proteasome, and JNK suggests a multifaceted regulatory role for Pramel53. The direct inhibition targeting specific kinases within the MAPK and PI3K/Akt pathways emphasizes its involvement in modulating these key signaling cascades. These mechanisms of inhibition collectively underscore Pramel53's significance in the broader context of cellular regulation and its potential impact on cellular processes. Disrupting Pramel53 function through various inhibitors alters the normal operation of these pathways, leading to changes in cellular processes and, presumably, the downstream functional consequences associated with Pramel53 activity. In conclusion, Pramel53, with its predicted cytoplasmic activity, emerges as a gene with intricate roles in cellular regulation, potentially influencing diverse signaling pathways. The inhibition of Pramel53 by various chemicals provides a glimpse into its complex involvement in cellular processes, shedding light on its importance in maintaining cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Indirect inhibitor impacting Pramel53 through the mTOR pathway. Rapamycin suppresses mTOR, influencing downstream events and leading to altered cellular processes and impaired function of Pramel53. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits Pramel53 indirectly through the p38 MAPK pathway. SB203580 suppresses p38 MAPK activity, influencing downstream events and leading to altered cellular processes and impaired function of Pramel53. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Indirect inhibitor impacting Pramel53 through the PI3K/Akt pathway. LY294002 suppresses PI3K, disrupting downstream Akt signaling, leading to altered cellular processes and impaired function of Pramel53. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Indirect inhibitor affecting Pramel53 through the ubiquitin-proteasome system. Bortezomib inhibits the proteasome, leading to altered protein degradation pathways and impaired function of Pramel53. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits Pramel53 indirectly through the MAPK/ERK pathway. PD98059 suppresses MEK activity, influencing downstream events and leading to altered cellular processes and impaired function of Pramel53. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Indirect inhibitor affecting Pramel53 through the ubiquitin-proteasome system. MG-132 inhibits the proteasome, leading to altered protein degradation pathways and impaired function of Pramel53. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits Pramel53 indirectly through the JNK pathway. SP600125 suppresses JNK activity, influencing downstream events and leading to altered cellular processes and impaired function of Pramel53. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Indirect inhibitor impacting Pramel53 through the PI3K/Akt pathway. Wortmannin inhibits PI3K, disrupting downstream Akt signaling, leading to altered cellular processes and impaired function of Pramel53. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Direct inhibitor targeting RAF kinase and impacting Pramel53 through the MAPK pathway. Sorafenib inhibits RAF, disrupting downstream signaling and leading to altered cellular processes and impaired function of Pramel53. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
Direct inhibitor of AMP-activated protein kinase (AMPK), influencing Pramel53 through the AMPK pathway. A769662 activates AMPK, leading to altered cellular processes and impaired function of Pramel53. | ||||||